Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply ...

As Adam Fein of Drug Channels Institute puts it, these forces are finally puncturing the “ gross-to-net bubble ”—the vast gap ...

For 2026, the plan features significantly lower out-of-pocket costs for members who use the plan’s “narrow network” that ...